A new approach to protein degradation

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches.

or why not drop us an email

About us

Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.

Targeted Protein Degradation

Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Lead by experts in the field

Based in BioCity in Scotland, Amphista has assembled an impressive team of successful entrepreneurs and senior industry executives including Dr Raj Parekh (Chairman) and Dr Nicola Thompson (CEO), alongside a globally recognized scientific team with deep expertise in the field of protein degradation.


Meet The Team

Find out more about the people behind Amphista Therapeutics.


Amphista is searching for innovative, and highly motivated individuals who enjoy teamwork and are comfortable working in a fast-paced entrepreneurial environment.

Find Out More

Drop us a line

We are here to answer any question you may have

By submitting this form you agree to our Terms & Conditions and Privacy Policy.

Our Address

BioCity, Bo'Ness Rd, Newhouse, Chapelhall, Motherwell, ML1 5UH, UK


Registered Address

158-160 North Gower Street, London, England, NW1 2ND, UK